Update to “guidelines on COVID-19 vaccination in patients with immune-mediated rheumatic diseases: a Brazilian Society of Rheumatology task force”

Impacts of the 2019 pandemic of severe acute respiratory syndrome–coronavirus 2 on the quality of life of patients with inflammatory rheumatic diseases

“…The findings of this study support those of several previous reports, which concluded that vaccines were well tolerated by those with RA, PsA, or SLE and that the occurrence of serious side effects or exacerbations was rare. Furthermore, vaccination had a beneficial effect on the psychosocial well-being of patients, who reported feeling safer, had more social contacts, and visited more public places, leading to a higher QoL (10)(11)(12). Additionally, previous studies reported significantly reduced immunoglobulin G responses to vaccination in SLE patients treated with immunosuppressants.…”

COVID-19 vaccine confidence in the post-vaccination era: Perceptions among adults with immune-mediated inflammatory diseases

“…In the context of patients with IMID, vaccines should ideally be administered before the planned immunosuppression or during disease quiescence in order to maximize vaccine immunogenicity [ 1 ]. More recently, massive coronavirus disease 2019 (COVID-19) vaccination rollouts have started across the globe, with vulnerable people, including those with immunocompromising conditions, generally being granted priority for vaccination [ [2] , [3] , [4] ]. In support of widespread recommendations for COVID-19 vaccination of high-risk individuals, the Brazilian registry of IMID patients infected with COVID-19 (ReumaCoV) has shown that high levels of immunosuppression are associated with unfavorable outcomes of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection [ 5 ].…”